Alkem Laboratories said its medical devices subsidiary will acquire up to a 55% stake in Switzerland-based Occlutech Holding AG for 99.4 million euros (about $118 million), marking its entry into advanced cardiovascular devices. The transaction, expected to close by June 2026 subject to regulatory approvals and final agreements, will expand Alkem MedTech’s presence in Continue Reading
